MDER (Medera) Total Stockholders Equity: $-6.09 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Medera Total Stockholders Equity?

Medera MDER Total Stockholders Equity is $-6.09 Mil as of Jun. 2024.

Medera's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $-6.09 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Medera's Book Value per Share for the quarter that ended in Jun. 2024 was $-0.09. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Medera's Debt-to-Equity for the quarter that ended in Jun. 2024 was -1.44.

Medera  (NAS:MDER) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Medera's Book Value per Share for the quarter that ended in Jun. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-6.088-0)/66.619
=-0.09

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Medera's Debt-to-Equity for the quarter that ended in Jun. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(8.742 + 0) / -6.088
=-1.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medera Total Stockholders Equity Related Terms

Medera Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Medera's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medera Total Stockholders Equity Chart

Medera Annual Data
Trend Dec22 Dec23
Total Stockholders Equity
-21.80 -10.91

Medera Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
Total Stockholders Equity -21.80 0.00 -10.91 -6.09
What does a Total Stockholders Equity of $-6.09 Mil mean?
Medera (MDER) has a Total Stockholders Equity of $-6.09 Mil as of Jun. 2024. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Medera and its competitors.
Is Medera's Total Stockholders Equity too high?
Medera's current Total Stockholders Equity is $-6.09 Mil.
How does Medera's Total Stockholders Equity compare to ?
Medera's Total Stockholders Equity of $-6.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Medera and its competitors. Medera's current Total Stockholders Equity is $-6.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medera stock overvalued right now?
Medera (MDER) has a current Total Stockholders Equity of $-6.09 Mil. The current Total Stockholders Equity is $-6.09 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Medera (MDER), the current Total Stockholders Equity is $-6.09 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medera Business Description

Comparable Companies
Address 6 Tide Street, 2nd Floor, Boston, MA, USA, 02210
Medera Inc is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates through two arms, namely: (1) pre-clinical disease modeling and drug discovery under Medera's Novoheart brand, which includes its bioengineered human mini-heart technology platform and related state-of-the-art technologies for preclinical screening; and (2) clinical development of novel therapies under Medera's Sardocor brand, which aspires to create the shortest regulatory path to clinic for advancing next-generation gene therapies (by leveraging the above Novoheart platform), in particular, for cardiovascular diseases.